» Articles » PMID: 19616885

Transplantation of Primed or Unprimed Mouse Embryonic Stem Cell-derived Neural Precursor Cells Improves Cognitive Function in Alzheimerian Rats

Overview
Journal Differentiation
Publisher Elsevier
Date 2009 Jul 21
PMID 19616885
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that is characterized by progressive and irreversible decline of memory. Neuropathological features include the progressive degeneration of cholinergic neurons in the forebrain cholinergic projection system especially nucleus basalis of Meynert (nbM). New cell therapeutic approaches for the replacement of degenerated cells are being researched. The aim of this study was to investigate the production of cholinergic neurons from mouse embryonic stem cells (ESCs) and potential for utilizing ESC-derived neuronal precursor cells (NPCs) and primed NPCs (PNPCs) for cell restorative therapy in a rodent model of AD. NPCs were produced by growth factor-mediated selection under serum-free conditions and differentiated better into cholinergic neurons when NPCs primed with Shh (approximately 22%) in comparison with different cholinergic promoting factors. Behavioral assessment of unilateral nbM ibotenic acid-lesioned rats by Morris water maze and spatial probe test revealed a significant behavioral improvement in memory deficits following transplantation with NPCs and/or PNPCs. Immunohistochemical analysis revealed that the majority (approximately 70%) of the NPCs and/or PNPCs retained neuronal phenotype and approximately 40% of them had a cholinergic cell phenotype following transplantation with no tumor formation, indicating that these may be safe for transplantation. This experimental study has important implications as it suggests that the transplantation of mouse ESC-derived NPCs and/or following commitment to a cholinergic cell phenotype can promote behavioral recovery in a rodent model of AD.

Citing Articles

Proposed Mechanisms of Cell Therapy for Alzheimer's Disease.

Belousova E, Salikhova D, Maksimov Y, Nebogatikov V, Sudina A, Goldshtein D Int J Mol Sci. 2024; 25(22).

PMID: 39596443 PMC: 11595163. DOI: 10.3390/ijms252212378.


A Comprehensive Review on Preclinical Alzheimer's Disease Models: Evaluating their Clinical Relevance.

Kushwaha V, Kumar Sahu K Curr Pharm Biotechnol. 2024; 26(2):186-207.

PMID: 39161136 DOI: 10.2174/0113892010331845240802073645.


Neuro-regeneration or Repair: Cell Therapy of Neurological Disorders as A Way Forward.

Song X, Fan C, Rahman A, Choudhary M, Wang X Curr Neuropharmacol. 2024; 22(14):2272-2283.

PMID: 38939990 PMC: 11451317. DOI: 10.2174/1570159X22666240509092903.


Therapeutic role of neural stem cells in neurological diseases.

Yang L, Liu S, Liu Y, Zhu F, Xiong M, Hu D Front Bioeng Biotechnol. 2024; 12:1329712.

PMID: 38515621 PMC: 10955145. DOI: 10.3389/fbioe.2024.1329712.


Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development.

Dave B, Shah Y, Maheshwari K, Mansuri K, Prajapati B, Postwala H Cell Mol Neurobiol. 2023; 43(8):3847-3884.

PMID: 37725199 PMC: 11407742. DOI: 10.1007/s10571-023-01408-7.